← Leaderboards
Min Hee Kang
Texas Tech University Health Scis Center
$3,394,606
Attributed
$4,770,010
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $926.8K · FY2011–23$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,770,010 · 4
By mechanism
R01$4,325,616 · 3
R15$444,394 · 1
Top collaborators
- Charles Patrick Reynolds6 shared
Most similar at Texas Tech University Health Scis Center
Same institution · by research overlap
- Charles Patrick Reynolds$10,127,129
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingCell LinePharmaceutical PreparationsNeuroblastomaResponseNeuroblastoma CellHigh RiskMalignant Childhood NeoplasmRecurrenceRecurrent DiseaseCollaborationsPediatric Oncology GroupCancer CellChildAntibodiesBaseCytokineIsotretinoinDifferentiation InducerMycn GeneImmunotherapyIn VivoDiagnosisEstablished Cell Line
Grant awards (13)
MYC activation in tumor progression of neuroblastoma$365,574
R01 · FY2023 · CA · contact PI
MYC activation in tumor progression of neuroblastoma$365,572
R01 · FY2022 · CA · contact PI
MYC activation in tumor progression of neuroblastoma$388,113
R01 · FY2021 · CA · contact PI
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines$531,922
R01 · FY2020 · CA
MYC activation in tumor progression of neuroblastoma$394,841
R01 · FY2020 · CA · contact PI
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines$520,798
R01 · FY2019 · CA
MYC activation in tumor progression of neuroblastoma$361,698
R01 · FY2019 · CA · contact PI
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines$553,437
R01 · FY2018 · CA
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma$284,060
R01 · FY2016 · CA · contact PI
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma$1
R01 · FY2015 · CA · contact PI
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma$275,539
R01 · FY2014 · CA · contact PI
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma$284,061
R01 · FY2013 · CA · contact PI
Altered Glycolytic Pathway in in vitro Models of leukemia developed in hypoxia$444,394
R15 · FY2011 · CA · contact PI